211 related articles for article (PubMed ID: 35882862)
1. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C; Andreani C; Vale G; Berto S; Melegari M; Crouch AC; Baluya DL; Kemble G; Hodges K; Starrett J; Politi K; Starnes SL; Lorenzini D; Raso MG; Solis Soto LM; Behrens C; Kadara H; Gao B; Wistuba II; Minna JD; McDonald JG; Scaglioni PP
Nat Commun; 2022 Jul; 13(1):4327. PubMed ID: 35882862
[TBL] [Abstract][Full Text] [Related]
2. Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis.
Padanad MS; Konstantinidou G; Venkateswaran N; Melegari M; Rindhe S; Mitsche M; Yang C; Batten K; Huffman KE; Liu J; Tang X; Rodriguez-Canales J; Kalhor N; Shay JW; Minna JD; McDonald J; Wistuba II; DeBerardinis RJ; Scaglioni PP
Cell Rep; 2016 Aug; 16(6):1614-1628. PubMed ID: 27477280
[TBL] [Abstract][Full Text] [Related]
3. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma.
Gouw AM; Eberlin LS; Margulis K; Sullivan DK; Toal GG; Tong L; Zare RN; Felsher DW
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4300-4305. PubMed ID: 28400509
[TBL] [Abstract][Full Text] [Related]
4. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
Yan WY; Cai J; Wang JN; Gong YS; Ding XB
Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996
[TBL] [Abstract][Full Text] [Related]
5. Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.
Terado T; Kim CJ; Ushio A; Minami K; Tambe Y; Kageyama S; Kawauchi A; Tsunoda T; Shirasawa S; Tanaka H; Inoue H
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35894141
[TBL] [Abstract][Full Text] [Related]
6. SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.
Ruiz CF; Montal ED; Haley JA; Bott AJ; Haley JD
FASEB J; 2020 Aug; 34(8):10574-10589. PubMed ID: 32568455
[TBL] [Abstract][Full Text] [Related]
7. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
Müller F; Lim JKM; Bebber CM; Seidel E; Tishina S; Dahlhaus A; Stroh J; Beck J; Yapici FI; Nakayama K; Torres Fernández L; Brägelmann J; Leprivier G; von Karstedt S
Cell Death Differ; 2023 Feb; 30(2):442-456. PubMed ID: 36443441
[TBL] [Abstract][Full Text] [Related]
8. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
9. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
[TBL] [Abstract][Full Text] [Related]
10. Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function.
Vu NT; Kim M; Stephenson DJ; MacKnight HP; Chalfant CE
Mol Cancer Res; 2022 Sep; 20(9):1429-1442. PubMed ID: 35560154
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
[TBL] [Abstract][Full Text] [Related]
12. Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.
Liu X; Hai Y; Dong J; Xu L; Hou W; Su J; Ren W; Liu D
Int J Oncol; 2022 Dec; 61(6):. PubMed ID: 36321791
[TBL] [Abstract][Full Text] [Related]
13. Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.
Li C; Yin X; Liu Z; Wang J
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499358
[TBL] [Abstract][Full Text] [Related]
14. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
15. Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
Zhou X; Kang J; Zhang L; Cheng Y
Cancer Chemother Pharmacol; 2023 Aug; 92(2):119-134. PubMed ID: 37318525
[TBL] [Abstract][Full Text] [Related]
16. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
17. Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS
Miao Q; Deng WQ; Lyu WY; Sun ZT; Fan SR; Qi M; Qiu SH; Zhu YR; Lin JP; Chen MF; Deng LJ
Free Radic Biol Med; 2023 Aug; 204():301-312. PubMed ID: 37217090
[TBL] [Abstract][Full Text] [Related]
18. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.
Svensson RU; Parker SJ; Eichner LJ; Kolar MJ; Wallace M; Brun SN; Lombardo PS; Van Nostrand JL; Hutchins A; Vera L; Gerken L; Greenwood J; Bhat S; Harriman G; Westlin WF; Harwood HJ; Saghatelian A; Kapeller R; Metallo CM; Shaw RJ
Nat Med; 2016 Oct; 22(10):1108-1119. PubMed ID: 27643638
[TBL] [Abstract][Full Text] [Related]
20. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.
Kim D; Min D; Kim J; Kim MJ; Seo Y; Jung BH; Kwon SH; Ro H; Lee S; Sa JK; Lee JY
J Exp Clin Cancer Res; 2023 Dec; 42(1):338. PubMed ID: 38093368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
